Tumor Necrosis Factor Receptors 6 Alpha & 6 Beta
    3.
    发明申请
    Tumor Necrosis Factor Receptors 6 Alpha & 6 Beta 审中-公开
    肿瘤坏死因子受体6 Alpha&6 Beta

    公开(公告)号:US20060234285A1

    公开(公告)日:2006-10-19

    申请号:US11419656

    申请日:2006-05-22

    CPC classification number: G01N33/57488 A61K38/00 C07K14/70578 C07K14/7151

    Abstract: The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α & -6β polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6α & -6β activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

    Abstract translation: 本发明涉及新型肿瘤坏死因子受体蛋白。 特别地,提供编码人TNFR-6α和-6β蛋白的分离的核酸分子。 还提供了TNFR-6α和-6β多肽,载体,宿主细胞和用于制备它们的重组方法。 本发明还涉及鉴定TNFR-6α和-6β活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测免疫系统相关疾病的诊断方法和用于治疗免疫系统相关疾病的治疗方法。

    Chemotactic cytokine III
    4.
    发明申请
    Chemotactic cytokine III 审中-公开
    趋化性细胞因子III

    公开(公告)号:US20060073573A1

    公开(公告)日:2006-04-06

    申请号:US11244394

    申请日:2005-10-06

    CPC classification number: C07K14/52 A61K38/00 C07K14/521 Y02A50/423

    Abstract: Human chemotactic cytokine III polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, cerebral ischemia, glomerulonephritis, HTLV-1 related diseases and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding chemotactic cytokine III and for detecting altered levels of the polypeptide in a host.

    Abstract translation: 公开了人类趋化性细胞因子III多肽和编码这种趋化性细胞因子的DNA(RNA)以及通过重组技术产生此类多肽的方法。 还公开了利用这种趋化性细胞因子治疗白血病,肿瘤,慢性感染,自身免疫疾病,纤维化病症,伤口愈合和牛皮癣的方法。 针对这种趋化性细胞因子的拮抗剂及其作为治疗类风湿性关节炎,自身免疫和慢性和急性炎症和感染性疾病,过敏反应,前列腺素不依赖性发烧,脑缺血,肾小球肾炎,HTLV-1相关疾病和骨髓衰竭的治疗用途 也被披露。 还公开了用于检测与核酸序列中的突变和多肽的改变的浓度相关的疾病的诊断测定。 还公开了用于检测编码趋化性细胞因子III的多核苷酸中的突变并用于检测宿主中多肽的改变水平的诊断测定。

    Pancreas-derived plasminogen activator inhibitor
    5.
    发明申请
    Pancreas-derived plasminogen activator inhibitor 审中-公开
    胰腺来源的纤溶酶原激活物抑制剂

    公开(公告)号:US20060045878A1

    公开(公告)日:2006-03-02

    申请号:US11048774

    申请日:2005-02-03

    Abstract: The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions and diagnostic methods for detecting pathologic disorders.

    Abstract translation: 本发明涉及纤溶酶原激活物抑制剂蛋白家族的新成员。 特别地,提供编码胰腺衍生的纤溶酶原激活物抑制蛋白的分离的核酸分子。 还提供了胰腺来源的纤溶酶原激活物抑制剂多肽,载体,宿主细胞和用于制备它们的重组方法。 本发明还涉及用于治疗生理和病理疾病状况的方法以及用于检测病理学疾病的诊断方法。

Patent Agency Ranking